## Jacques W M Lenders

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6060547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1915-1942.	1.8	2,031
2	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	6.3	1,462
3	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
4	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	5.5	595
5	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	5.1	477
6	An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary Aldosteronism. Hypertension, 2014, 63, 151-160.	1.3	475
7	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	1.8	447
8	Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism. Annals of Internal Medicine, 2009, 151, 329.	2.0	395
9	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel–Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	13.9	335
10	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology, 2007, 25, 2262-2269.	0.8	316
11	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749.	1.3	304
12	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	1.5	282
13	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	3.2	277
14	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
15	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients withSuccinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 779-786.	1.8	262
16	SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncology, The, 2010, 11, 366-372.	5.1	256
17	Cardiovascular manifestations of phaeochromocytoma. Journal of Hypertension, 2011, 29, 2049-2060.	0.3	224
18	Plasma Metanephrines in the Diagnosis of Pheochromocytoma. Annals of Internal Medicine, 1995, 123, 101.	2.0	222

#	Article	IF	CITATIONS
19	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol- <i>O</i> -Methyltransferase Within Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2175-2185.	1.8	219
20	Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 739-746.	5.5	208
21	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.3	190
22	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
23	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	1.6	169
24	Self-Measurement of Blood Pressure at Home Reduces the Need for Antihypertensive Drugs. Hypertension, 2007, 50, 1019-1025.	1.3	164
25	Denervation of Carotid Baro―and Chemoreceptors in Humans. Journal of Physiology, 2003, 553, 3-11.	1.3	146
26	An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 75-84.	1.2	129
27	Cenotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	1.3	127
28	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	1.8	127
29	Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clinical Pharmacology and Therapeutics, 1990, 48, 410-418.	2.3	125
30	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	1.5	123
31	ENDOCRINE DISORDERS IN PREGNANCY: Pheochromocytoma and pregnancy: a deceptive connection. European Journal of Endocrinology, 2012, 166, 143-150.	1.9	122
32	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	1.5	121
33	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clinica Chimica Acta, 2017, 470, 115-124.	0.5	116
34	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. Annals of the New York Academy of Sciences, 2006, 1073, 332-347.	1.8	115
35	Is the Excess Cardiovascular Morbidity in Pheochromocytoma Related to Blood Pressure or to Catecholamines?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1100-1106.	1.8	114
36	Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinology and Metabolism, 2017, 32, 152.	1.3	113

#	Article	IF	CITATIONS
37	Long-Term Effects of Carotid Sinus Denervation on Arterial Blood Pressure in Humans. Circulation, 2002, 105, 1329-1335.	1.6	110
38	ls Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. Clinical Chemistry, 2007, 53, 352-354.	1.5	110
39	Orthostatic Tolerance, Cerebral Oxygenation, and Blood Velocity in Humans With Sympathetic Failure. Stroke, 2000, 31, 1608-1614.	1.0	106
40	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. Clinical Science, 1995, 88, 533-542.	1.8	105
41	The pathophysiology of the vasovagal response. Heart Rhythm, 2018, 15, 921-929.	0.3	101
42	Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 16-24.	1.8	99
43	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 62-69.	0.8	98
44	Biochemical diagnosis of phaeochromocytoma using plasmaâ€free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clinical Endocrinology, 2014, 80, 478-486.	1.2	96
45	Cardiovascular Pharmacology of Purines. Clinical Science, 1997, 92, 13-24.	1.8	93
46	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 375-384.	1.8	90
47	Pheochromocytoma as an endocrine emergency. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 121-128.	2.6	87
48	Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2381-2391.	1.8	85
49	Does it matter whether blood pressure measurements are taken with subjects sitting or supine?. Journal of Hypertension, 1998, 16, 263-268.	0.3	83
50	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2017, 177, 103-113.	1.9	82
51	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	4.3	80
52	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine, 2017, 56, 495-503.	1.1	79
53	Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515.	2.2	76
54	Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Reviews, 2017, 38, 103-122.	8.9	76

#	Article	IF	CITATIONS
55	Baroreflex and chemoreflex function after bilateral carotid body tumor resection. Journal of Hypertension, 2003, 21, 591-599.	0.3	75
56	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.3	74
57	Plasma metanephrines in renal failure. Kidney International, 2005, 67, 668-677.	2.6	73
58	Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	2.3	72
59	Pheochromocytoma – update on disease management. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 11-26.	1.4	70
60	New Advances in the Biochemical Diagnosis of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 29-40.	1.8	68
61	Somatic <i>SDHB</i> Mutation in an Extraadrenal Pheochromocytoma. New England Journal of Medicine, 2007, 357, 306-308.	13.9	68
62	Role of the wrist cuff in forearm plethysmography. Clinical Science, 1991, 80, 413-417.	1.8	67
63	Correlation Between In Vivo <sup>18</sup> F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2014, 55, 1253-1259.	2.8	67
64	The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. Journal of Hypertension, 2006, 24, 1541-1548.	0.3	66
65	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1223-E1233.	1.8	66
66	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Annals of Surgery, 2020, 272, 1125-1132.	2.1	66
67	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. Endocrinology and Metabolism Clinics of North America, 2006, 35, 699-724.	1.2	65
68	Plasma Metanephrine for Assessing the Selectivity of Adrenal Venous Sampling. Hypertension, 2013, 62, 1152-1157.	1.3	65
69	Stability of Urinary Fractionated Metanephrines and Catecholamines during Collection, Shipment, and Storage of Samples. Clinical Chemistry, 2007, 53, 268-272.	1.5	64
70	Influence of body and arm position on blood pressure readings. Journal of Hypertension, 2003, 21, 237-241.	0.3	63
71	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	1.1	60
72	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59

#	Article	IF	CITATIONS
73	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	1.9	58
74	Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology, 2012, 79, 793-796.	1.5	57
75	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2175-2185.	1.8	57
76	Reproducibility of ambulatory blood pressure monitoring in daily practice. Journal of Human Hypertension, 1999, 13, 303-308.	1.0	55
77	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
78	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	4.6	54
79	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2013, 19, 3787-3795.	3.2	53
80	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	2.8	53
81	Somatostatin Analog Octreotide (SMS 201-995) Prevents the Decrease in Blood Pressure After Oral Glucose Loading in the Elderly*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 752-756.	1.8	52
82	MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. European Journal of Endocrinology, 2016, 175, R135-R145.	1.9	52
83	Long-term effects of unilateral carotid endarterectomy on arterial baroreflex function. Clinical Autonomic Research, 2004, 14, 72-79.	1.4	51
84	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	1.3	51
85	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	0.5	50
86	Effect of Chronic Smoking on Endothelium-Dependent Vascular Relaxation in Humans. Clinical Science, 1993, 85, 51-55.	1.8	49
87	Presynaptic Inhibition of Norepinephrine Release From Sympathetic Nerve Endings by Endogenous Adenosine. Hypertension, 1996, 27, 933-938.	1.3	49
88	Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clinical Biochemist Reviews, 2017, 38, 69-100.	3.3	46
89	Mutations associated with succinate dehydrogenase <scp>d</scp> â€related malignant paragangliomas. Clinical Endocrinology, 2008, 68, 561-566.	1.2	44
90	Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Brazilian Journal of Medical and Biological Research, 2000, 33, 1157-1169.	0.7	43

#	Article	IF	CITATIONS
91	Do we need to evaluate diastolic blood pressure in patients with suspected orthostatic hypotension?. Clinical Autonomic Research, 2017, 27, 167-173.	1.4	42
92	Pheochromocytoma and Pregnancy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 605-617.	1.2	42
93	Prevalence of primary aldosteronism in primary care: a cross-sectional study. British Journal of General Practice, 2018, 68, e114-e122.	0.7	41
94	Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection. Clinical Chemistry, 2003, 49, 1951-1953.	1.5	40
95	Prevalence of the white-coat effect at multiple visits before and during treatment. Journal of Hypertension, 2006, 24, 2357-2363.	0.3	40
96	Prospective evaluation of non-pharmacological treatment in vasovagal syncope. Europace, 2010, 12, 567-573.	0.7	39
97	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. European Journal of Endocrinology, 2018, 178, R1-R9.	1.9	39
98	Cardiovascular Responses to Stress after Carotid Baroreceptor Denervation in Humans. Annals of the New York Academy of Sciences, 2004, 1018, 515-519.	1.8	36
99	Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 1121.	1.7	36
100	The Influence of Age and Blood Pressure on the Hemodynamic and Humoral Response to Headâ€⊎p Tilt. Journal of the American Geriatrics Society, 1989, 37, 528-532.	1.3	35
101	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	0.6	35
102	Clinical Pharmacokinetics and Efficacy of Renin Inhibitors. Clinical Pharmacokinetics, 1995, 29, 6-14.	1.6	34
103	Influence of the arm position on intra-arterial blood pressure measurement. Journal of Human Hypertension, 1998, 12, 157-160.	1.0	34
104	Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?. Hormone and Metabolic Research, 2017, 49, 969-976.	0.7	34
105	Arm position is important for blood pressure measurement. Journal of Human Hypertension, 1999, 13, 105-109.	1.0	32
106	Subtyping of Patients with Primary Aldosteronism: An Update. Hormone and Metabolic Research, 2017, 49, 922-928.	0.7	32
107	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	1.4	32
108	Neurocognitive Function in Dopamine-Î <sup>2</sup> -Hydroxylase Deficiency. Neuropsychopharmacology, 2011, 36, 1608-1619.	2.8	31

#	Article	IF	CITATIONS
109	Pharmacological treatment of aldosterone excess. , 2015, 154, 120-133.		31
110	Baroreflex Control of Muscle Sympathetic Nerve Activity After Carotid Body Tumor Resection. Hypertension, 2003, 42, 143-149.	1.3	30
111	Semiquantitative <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. Journal of Nuclear Medicine, 2015, 56, 839-846.	2.8	30
112	Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 224-232.	1.8	30
113	Approach to the Patient: Perioperative Management of the Patient with Pheochromocytoma or Sympathetic Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3088-3102.	1.8	30
114	The position of the arm during blood pressure measurement in sitting position. Blood Pressure Monitoring, 2006, 11, 309-313.	0.4	28
115	Should every patient diagnosed with a phaeochromocytoma have a <sup>123</sup> <scp>I</scp> â€ <scp>MIBG</scp> scintigraphy?. Clinical Endocrinology, 2014, 81, 329-333.	1.2	28
116	Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review. Hormone and Metabolic Research, 2017, 49, 943-950.	0.7	28
117	Effects of Treating Primary Aldosteronism on Renal Function. Journal of Clinical Hypertension, 2017, 19, 290-295.	1.0	28
118	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	1.2	28
119	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27
120	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	1.8	27
121	Reduced imprecision of the radioenzymatic assay of plasma catecholamines by improving the stability of the internal standards. Clinica Chimica Acta, 1986, 156, 221-225.	0.5	26
122	Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy. Hypertension, 2018, 71, 10-14.	1.3	26
123	Accuracy and Reproducibility of 30 Devices for Self-Measurement of Arterial Blood Pressure. American Journal of Hypertension, 1993, 6, 873-879.	1.0	25
124	Insulin stimulates epinephrine release under euglycemic conditions in humans. Metabolism: Clinical and Experimental, 1998, 47, 243-249.	1.5	25
125	Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R165-R173.	0.9	25
126	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. Current Hypertension Reports, 2002, 4, 250-255.	1.5	25

#	Article	IF	CITATIONS
127	Arterial baroreflex and peripheral chemoreflex function after radiotherapy for laryngeal or pharyngeal cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1203-1210.	0.4	25
128	Side effects of ambulatory blood pressure monitoring. Blood Pressure Monitoring, 2005, 10, 151-155.	0.4	25
129	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. European Journal of Endocrinology, 2014, 170, 349-357.	1.9	25
130	Antihypertensive Treatment and Postprandial Blood Pressure Reduction in the Elderly. Gerontology, 1987, 33, 363-368.	1.4	24
131	Influence of different supine body positions on blood pressure. Journal of Hypertension, 2000, 18, 1731-1736.	0.3	24
132	Pathophysiology and Diagnosis of Disorders of the Adrenal Medulla: Focus on Pheochromocytoma. , 2014, 4, 691-713.		24
133	Value of the plasma norepinephrine/3,4-dihydroxyphenylglycol ratio for the diagnosis of pheochromocytoma. American Journal of Medicine, 1992, 92, 147-152.	0.6	23
134	Sympathoadrenal activation and the dumping syndrome after gastric surgery. Clinical Autonomic Research, 2000, 10, 301-308.	1.4	22
135	Sympathoinhibition by Atorvastatin in Hypertensive Patients. Circulation Journal, 2010, 74, 2622-2626.	0.7	22
136	Sympathoinhibitory effect of statins in chronic heart failure. Clinical Autonomic Research, 2010, 20, 73-78.	1.4	22
137	Differential Effects of Low- and High-Intensity Lower Body Negative Pressure on Noradrenaline and Adrenaline Kinetics in Humans. Clinical Science, 1996, 90, 337-343.	1.8	21
138	Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 83-97.	1.1	21
139	Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clinical Pharmacology and Therapeutics, 1993, 54, 567-577.	2.3	20
140	A Test of the "Epinephrine Hypothesis―in Humans. Hypertension, 1999, 33, 36-43.	1.3	20
141	Adrenomedullary Secretion of Epinephrine Is Increased in Mild Essential Hypertension. Hypertension, 1997, 29, 1303-1308.	1.3	20
142	Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD. American Journal of Kidney Diseases, 2018, 72, 907-909.	2.1	19
143	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	1.8	19
144	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	1.8	19

#	Article	IF	CITATIONS
145	The effect of crossing legs on blood pressure. Blood Pressure Monitoring, 2007, 12, 189-193.	0.4	18
146	Central and cerebrovascular effects of leg crossing in humans with sympathetic failure. Clinical Science, 2010, 118, 573-581.	1.8	18
147	Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review. Clinical Endocrinology, 2015, 83, 622-628.	1.2	18
148	Left Ventricular Structural and Functional Alterations in Patients With Pheochromocytoma/Paraganglioma Before and After Surgery. JACC: Cardiovascular Imaging, 2020, 13, 2498-2509.	2.3	18
149	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. European Journal of Cancer, 2022, 169, 32-41.	1.3	18
150	Sympathetic nervous system function in HIV-associated adipose redistribution syndrome. Aids, 2006, 20, 773-775.	1.0	17
151	Prevalence and Persistence of Masked Hypertension in Treated Hypertensive Patients. American Journal of Hypertension, 2007, 20, 1258-1265.	1.0	17
152	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	1.9	17
153	Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome. Gynecological Endocrinology, 2018, 34, 20-24.	0.7	17
154	Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. Journal of Clinical Sleep Medicine, 2021, 17, 629-637.	1.4	17
155	Biochemical diagnosis of pheochromocytoma and paraganglioma. Annales D'Endocrinologie, 2009, 70, 161-165.	0.6	16
156	Compliance with periodic surveillance for Von-Hippel-Lindau disease. Genetics in Medicine, 2011, 13, 519-527.	1.1	16
157	The acute effect of cigarette smoking on the high-sensitivity CRP and fibrinogen biomarkers in chronic obstructive pulmonary disease patients. Biomarkers in Medicine, 2013, 7, 211-219.	0.6	16
158	Disparate effects of mental stress on plasma noradrenaline in young normotensive and hypertensive subjects. Journal of Hypertension, 1989, 7, 317???324.	0.3	15
159	Plasmaâ€free <i>vs</i> deconjugated metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2013, 79, 476-483.	1.2	15
160	Hydrochlorothiazide treatment increases the abundance of the NaCl cotransporter in urinary extracellular vesicles of essential hypertensive patients. American Journal of Physiology - Renal Physiology, 2017, 312, F1063-F1072.	1.3	15
161	Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome – a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1264-1272. 	1.1	14
162	Adrenoceptors on blood cells in patients with essential hypertension before and after mental stress. Journal of Hypertension, 1989, 7, 519-524.	0.3	13

#	Article	IF	CITATIONS
163	Antecedent Adrenaline Attenuates the Responsiveness to But Not the Release of Counterregulatory Hormones during Subsequent Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5462-5467.	1.8	13
164	Pitfall in HPLC Assay for Urinary Metanephrines: An Unusual Type of Interference Caused by Methenamine Intake. Clinical Chemistry, 2004, 50, 1097-1099.	1.5	13
165	Clinical presentation and longâ€ŧerm followâ€up of dopamine beta hydroxylase deficiency. Journal of Inherited Metabolic Disease, 2021, 44, 554-565.	1.7	13
166	Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?. European Journal of Endocrinology, 2020, 182, 499-509.	1.9	13
167	Rapid circulatory clearances and halfâ€lives of plasma free metanephrines. Clinical Endocrinology, 2012, 77, 484-485.	1.2	12
168	Computational analysis of liquid chromatography-tandem mass spectrometric steroid profiling in NCI H295R cells following angiotensin II, forskolin and abiraterone treatment. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 67-75.	1.2	12
169	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	1.6	12
170	Comparison of blood pressure response to exogenous epinephrine in hypertensive men and women. American Journal of Cardiology, 1988, 61, 1288-1291.	0.7	11
171	Catecholamine Phenotyping: Clues to the Diagnosis, Treatment, and Pathophysiology of Neurogenetic Disorders. Journal of Neurochemistry, 2002, 67, 1781-1790.	2.1	11
172	Plasma Metanephrine Levels Are Decreased in Type 1 Diabetic Patients with a Severely Impaired Epinephrine Response to Hypoglycemia, Indicating Reduced Adrenomedullary Stores of Epinephrine. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2057-2061.	1.8	11
173	The role of carotid chemoreceptors in the sympathetic activation by adenosine in humans. Clinical Science, 2004, 106, 75-82.	1.8	11
174	Supine or Sitting? Economic and other considerations for use of plasma metanephrines for diagnosis of phaeochromocytoma. Clinical Endocrinology, 2015, 82, 463-464.	1.2	11
175	Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. Clinical Chemistry, 2018, 64, 1780-1781.	1.5	11
176	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocrine Connections, 2018, 7, 1168-1177.	0.8	11
177	Genetic Deficiencies of Monoamine Oxidase Enzymes: A Key to Understanding the Function of the Enzymes in Humans. Advances in Pharmacology, 1997, 42, 297-301.	1.2	10
178	Haemodynamic actions of insulin. Current Opinion in Nephrology and Hypertension, 1998, 7, 99-106.	1.0	10
179	Bromide as marker for drug adherence in hypertensive patients. British Journal of Clinical Pharmacology, 2008, 65, 733-736.	1.1	10
180	Reproducibility of haemodynamic and plasma catecholamine responses to isometric exercise and mental arithmetic in normo- and hyper-tensive subjects. Clinical Science, 1988, 75, 615-619.	1.8	9

#	Article	IF	CITATIONS
181	Ephedrine Improves Microcirculation in the Diabetic Neuropathic Foot. Angiology, 1989, 40, 1030-1034.	0.8	9
182	Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. Journal of Hypertension, 2002, 20, 2275-2283.	0.3	9
183	Effect of glycyrrhetinic acid on 11β-hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clinical Science, 2002, 102, 203.	1.8	9
184	Which physiological mechanism is responsible for the increase in blood pressure during leg crossing?. Journal of Hypertension, 2008, 26, 433-437.	0.3	9
185	Pacing in vasovagal syncope: A physiological paradox?. Heart Rhythm, 2020, 17, 813-820.	0.3	9
186	Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy. Tubercle, 1983, 64, 125-128.	0.7	8
187	Interaction in COPD experiment (ICE): A hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Medical Hypotheses, 2010, 74, 277-280.	0.8	8
188	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	0.5	8
189	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World Journal of Urology, 2022, 40, 385-390.	1.2	8
190	Adenosine Attenuates the Vasoconstrictor Response to the Cold Pressor Test in Humans. Journal of Cardiovascular Pharmacology, 1991, 17, 1019-1022.	0.8	7
191	Intravenous instrumentation alters the autonomic state in humans. European Journal of Applied Physiology and Occupational Physiology, 1996, 73, 113-116.	1.2	7
192	Leg vasoconstriction during head-up tilt in patients with autonomic failure is not abolished. Journal of Applied Physiology, 2011, 110, 416-422.	1.2	7
193	A study of longer-time stability of plasma free metanephrines. Annals of Clinical Biochemistry, 2011, 48, 270-271.	0.8	7
194	A disease-specific Quality of Life questionnaire for primary aldosteronism. Endocrine Connections, 2019, 8, 389-397.	0.8	7
195	Cardiovascular responsiveness to norepinephrine in mild essential hypertension. American Journal of Cardiology, 1989, 63, 1231-1234.	0.7	6
196	Atrial Natriuretic Factor Potentiates the Human Forearm Vasoconstrictor Response to Sympathetic Stimulation. Clinical Science, 1994, 86, 275-283.	1.8	6
197	Transport within the Interstitial Space, Rather Than Membrane Permeability, Determines Norepinephrine Recovery in Microdialysis. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 840-846.	1.3	6
198	Should blood pressure be measured with the cuff on a bare arm?. Blood Pressure Monitoring, 2015, 20, 320-324.	0.4	6

#	Article	IF	CITATIONS
199	Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1929-1937.	1.4	6
200	The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects. Clinical Pharmacology and Therapeutics, 1986, 39, 353-357.	2.3	5
201	Clues to the Diagnosis of Pheochromocytoma from the Differential Tissue Metabolism of Catecholamines. Advances in Pharmacology, 1997, 42, 374-377.	1.2	5
202	Occam's razor; anaemia and orthostatic hypotension. Lancet, The, 2003, 362, 1282.	6.3	5
203	Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 418-423.	0.7	5
204	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. Discover Oncology, 2021, 12, 9.	0.8	5
205	Optimized procedures for testing plasma metanephrines in patients on hemodialysis. Scientific Reports, 2021, 11, 14706.	1.6	5
206	Long-Term Î <sup>2</sup> 1-Adrenergic Blockade Restores Adrenomedullary Activity in Primary Hypertension. Journal of Cardiovascular Pharmacology, 1997, 30, 338-342.	0.8	5
207	Comparison of two indices for forearm noradrenaline release in humans. Clinical Science, 2000, 99, 363.	1.8	4
208	Bronchodilation and Smoking Interaction in COPD: A Cohort Pilot Study to Assess Cardiovascular Risk. Respiration, 2012, 83, 125-132.	1.2	4
209	Single versus duplicate blood samples in ACTH stimulated adrenal vein sampling. Clinica Chimica Acta, 2013, 423, 15-17.	0.5	4
210	Patient characteristics do not predict the individual response to antihypertensive medication: a cross-over trial. Family Practice, 2018, 35, 67-73.	0.8	4
211	Assessing outcomes after adrenalectomy for unilateral primary aldosteronism. Surgery, 2019, 166, 1199-1200.	1.0	4
212	A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2019, 188, 38-47.	1.2	4
213	Low Quality of Reports on Blood Pressure in Patients Adrenalectomized for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2232-e2238.	1.8	4
214	Shortâ€acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction. Respirology, 2013, 18, 663-668.	1.3	3
215	Cigarette smoke retention and bronchodilation in patients with COPD. A controlled randomized trial. Respiratory Medicine, 2013, 107, 112-119.	1.3	3

#	Article	IF	CITATIONS
217	A pedunculated aldosteroneâ€producing adenoma drained by an extra vein causing puzzling results of adrenal vein sampling. Clinical Endocrinology, 2018, 89, 242-244.	1.2	3
218	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. Journal of Hypertension, 2020, 38, 1551-1558.	0.3	3
219	Pheochromocytoma and Paraganglioma. , 2019, , 523-531.		3
220	A prediction model for primary aldosteronism when the salt loading test is inconclusive. Endocrine Connections, 2018, 7, 1308-1314.	0.8	3
221	Pheochromocytoma Concealed By Chronic Methamphetamine Abuse. AACE Clinical Case Reports, 2020, 6, e212-e216.	0.4	3
222	A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial. Trials, 2011, 12, 37.	0.7	2
223	CD56 immunohistochemistry does not discriminate between cortisol-producing and aldosterone-producing adrenal cortical adenomas. Histopathology, 2011, 58, 994-996.	1.6	2
224	Resection of Pheochromocytoma in a Patient Requiring Coronary Artery Bypass Grafting: First Things First. AACE Clinical Case Reports, 2016, 2, e25-e29.	0.4	2
225	Current Trends in Genetics of Pheochromocytoma. , 0, , 30-40.		2
226	Catecholamines and Adrenergic Receptors. , 0, , 41-71.		2
227	Current Trends in Biochemical Diagnosis of Pheochromocytoma. , 0, , 72-92.		2
228	Normetanephrine and Metanephrine. , 2017, , 420-424.		1
229	Circulating adrenomedullin and B-type natriuretic peptide do not predict blood pressure fluctuations during pheochromocytoma resection: a cross-sectional study. European Journal of Endocrinology, 2021, 185, 507-514.	1.9	1
230	Current Trends in Localization of Pheochromocytoma. , 0, , 93-108.		1
231	Plasma free versus deconjugated metanephrines for diagnosis of pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, .	0.6	1
232	Is the plasma aldosterone-to-renin ratio associated with blood pressure response to treatment in general practice?. Family Practice, 2019, 36, 154-161.	0.8	1
233	Clinical Presentation of Pheochromocytoma. , 0, , 8-29.		1
234	Circulating adrenaline is not involved in the circadian blood pressure profile. Journal of Hypertension, 1995, 13, 1585???1588.	0.3	0

#	Article	IF	CITATIONS
235	Orthostatic Hypotension Due to Arterial Baroreflex Failure. , 0, , 141-143.		0
236	Treatment of Pheochromocytoma. , 0, , 109-113.		0
237	P51. Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease. Pregnancy Hypertension, 2011, 1, 297.	0.6	0
238	Response to Implementation of Rapid Cortisol During Adrenal Vein Sampling. Hypertension, 2014, 63, e89.	1.3	0
239	Response to Letter to the Editor from Berends et al: "Approach to the Patient: Perioperative Management of the Patient With Pheochromocytoma or Sympathetic Paragangliomaâ€: Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4980-e4981.	1.8	0
240	Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. Blood Pressure, 2021, 30, 1-8.	0.7	0
241	Normetanephrine and Metanephrine. , 2004, , 387-390.		0
242	Hoe betrouwbaar zijn de bloeddrukbepalingen met elektronische apparatuur?. , 2006, , 2381-2383.		0
243	ls Overexpression of the Hypoxia-Inducible Factor-1alpha Natural Antisense Transcript a Marker of the Malignant Potential of Phaeochromocytoma? , 2010, , P3-619-P3-619.		0
244	SDHB mutation testing in metastatic pheochromocytoma and paraganglioma: Is this required in patients with adrenaline-producing tumors?. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	0
245	Seasonal variation of plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	0
246	Paroxysmal Hypertension: Pheochromocytoma. Updates in Hypertension and Cardiovascular Protection, 2018, , 541-560.	0.1	0
247	Future Trends and Perspectives. , 0, , 114-119.		0